×
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

AbbVie's Parkinson's disease drug meets main goal in late-stage trial

Patients showed a statistically significant improvement when two fixed doses of the drug, tavapadon, as a monotherapy were compared to placebo, as measured on a rating scale.
Last Updated : 26 September 2024, 14:09 IST

Follow Us :

Comments
ADVERTISEMENT
Published 26 September 2024, 14:09 IST

Follow us on :

Follow Us